XML 33 R25.htm IDEA: XBRL DOCUMENT v3.23.3
CORRECTION OF ERRORS IN 2022 INTERIM FINANCIAL INFORMATION (Tables)
5 Months Ended
Jun. 30, 2023
Accounting Changes and Error Corrections [Abstract]  
SCHEDULE OF ERROR CORRECTIONS

SCHEDULE OF ERROR CORRECTIONS

             
Condensed Balance Sheets  For the six months ended June 30, 2022 (unaudited) 
   As previously reported   Adjustments   As Restated 
             
Total assets  $5,620,989   $   $5,620,989 
                
Total current liabilities   1,381,419        1,381,419 
                
Additional paid-in capital   41,184,654    (152,653)   41,032,001 
Accumulated deficit   (36,945,162)   152,653    (36,792,509)
Other   78        78 
Total stockholders’ equity   4,239,570        4,239,570 
                
Total liabilities and stockholders’ equity  $5,620,989   $   $5,620,989 

 

             
Condensed Statements of Operations  For the six months ended June 30, 2022 (unaudited) 
   As previously reported   Adjustments   As Restated 
             
Gross profit (loss)  $(11,279)  $   $(11,279)
                
Sales and marketing   194,067        194,067 
Research and development   558,029        558,029 
General and administrative   2,375,126    (152,653)   2,222,473 
Total operating expenses   3,127,222    (152,653)   2,974,569 
                
Total other income (expense)   (1,505,102)       (1,505,102)
                
Net income (loss)  $(4,643,603)  $152,653   $(4,490,950)
Net (loss) allocable to common stockholders  $(5,059,126)  $152,653   $(4,906,473)
(Loss) per share  $(1.16)  $0.04   $(1.12)
Weighted Average common shares outstanding   4,363,600    10,068    4,373,668 

 

 

             
Condensed Statements of Operations  For the three months ended June 30, 2022 (unaudited) 
   As previously reported   Adjustments   As Restated 
             
Gross profit (loss)  $(3,573)  $   $(3,573)
                
Sales and marketing   124,759        124,759 
Research and development   353,226        353,226 
General and administrative   1,883,843    (152,653)   1,731,190 
Total operating expenses   2,361,828    (152,653)   2,209,175 
                
Total other income (expense)   (1,342,114)       (1,342,114)
                
Net income (loss)  $(3,707,515)  $152,653   $(3,554,862)
Net (loss) allocable to common stockholders  $(3,835,723)  $152,653   $(3,683,070)
(Loss) per share  $(0.49)  $0.02   $(0.47)
Weighted Average common shares outstanding   7,821,515        7,821,515 

 

                
Condensed Statements of Cash Flows  For the six months ended June 30, 2022 (unaudited) 
   As previously reported   Adjustments   As Restated 
             
Net income (loss)  $(4,643,603)  $152,653   $(4,490,950)
                
Adjustments to reconcile net income (loss) to net cash used in operation activities               
Depreciation and amortization   94,705    (25,000)   69,705 
Non-cash charge settled in equity       1,299,507    1,299,507 
Prepaids and other current assets   (308,052)   (140,382)   (448,434)
Accrued and other liabilities   728,399    (921,718)   (193,320)
Other   1,047,540        1,047,540 
Net cash (used in) operations   (3,081,011)   365,060    (2,715,951)
                
Net cash (used in) investing activities   (120,957)       (120,957)
                
IPO Issuance costs       (365,060)   (365,060)
Others   6,552,318        6,552,318 
Net cash provided by financing activities   6,552,318    (365,060)   6,187,258 
                
Net cash increase (decrease) for period  $3,350,350   $   $3,350,350 

 

             
Condensed Statements of Changes in Stockholders’ Equity  June 30, 2022 (unaudited) 
   As previously reported   Adjustments   As Restated 
             
Common Stock  $78   $   $78 
Additional paid-in capital   41,184,654    (152,653)   41,032,001 
Accumulated deficit   (36,945,162)   152,653    (36,792,509)
Total stockholders’ equity  $4,239,570   $   $4,239,570